These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31953112)

  • 21. Provider perspectives and experiences following the integration of the prescription drug monitoring program into the electronic health record.
    Witry M; Marie BS; Reist J
    Health Informatics J; 2022; 28(3):14604582221113435. PubMed ID: 35829729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
    Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
    J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis.
    Hagemeier NE; Tudiver F; Brewster S; Hagy EJ; Ratliff B; Hagaman A; Pack RP
    Subst Abus; 2018 Jan; 39(1):89-94. PubMed ID: 28799863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A content review of online naloxone Continuing Education courses for pharmacists in states with standing orders.
    Carpenter DM; Roberts CA; Westrick SC; Ferreri SP; Kennelty KA; Look KA; Abraham O; Wilson C
    Res Social Adm Pharm; 2018 Oct; 14(10):968-978. PubMed ID: 29239777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences between pharmacists' perception of counseling and practice in the era of prescription drug misuse.
    Thornton JD; Anyanwu P; Tata V; Al Rawwad T; Fleming ML
    Pharm Pract (Granada); 2020; 18(1):1682. PubMed ID: 32206140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review.
    Johnston K; Alley L; Novak K; Haverly S; Irwin A; Hartung D
    J Am Pharm Assoc (2003); 2018; 58(5):568-576. PubMed ID: 30030040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists.
    Bakhireva LN; Bautista A; Cano S; Shrestha S; Bachyrycz AM; Cruz TH
    Subst Abus; 2018; 39(3):331-341. PubMed ID: 29043922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
    Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
    Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Community pharmacists' prescription intervention practices--exploring variations in practice in Norwegian pharmacies.
    Mandt I; Horn AM; Ekedahl A; Granas AG
    Res Social Adm Pharm; 2010 Mar; 6(1):6-17. PubMed ID: 20188324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacists' Role in Opioid Safety: A Focus Group Investigation.
    Hartung DM; Hall J; Haverly SN; Cameron D; Alley L; Hildebran C; O'Kane N; Cohen D
    Pain Med; 2018 Sep; 19(9):1799-1806. PubMed ID: 29016883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey.
    Alvin M; Picco L; Wood P; Mnatzaganian G; Nielsen S
    Int J Clin Pharm; 2021 Apr; 43(2):411-419. PubMed ID: 32951182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol for the Optimizing Naloxone Dispensing in Pharmacies (ONDP) Online Continuing Education Program: A Randomized Controlled Trial.
    Cid A; Patten A; Beazely M; Grindrod K; Yessis J; Chang F
    Pharmacy (Basel); 2022 Feb; 10(1):. PubMed ID: 35202073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
    Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
    Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparing student pharmacists to identify opioid misuse, prevent overdose and prescribe naloxone.
    Skoy E; Eukel H; Frenzel J; Werremeyer A
    Curr Pharm Teach Learn; 2019 May; 11(5):522-527. PubMed ID: 31171255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review.
    Thakur T; Frey M; Chewning B
    J Am Pharm Assoc (2003); 2020; 60(1):178-194. PubMed ID: 31371179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
    Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
    J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prescription drug monitoring program use and utility by Washington State pharmacists: A mixed-methods study.
    Pett RG; Mancl L; Revere D; Stergachis A
    J Am Pharm Assoc (2003); 2020; 60(1):57-65. PubMed ID: 31753615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of an integrated opioid and medical marijuana prescription drug monitoring program.
    Rickles NM; Wakai S; Karim-Nejad L
    J Am Pharm Assoc (2003); 2021; 61(4):408-417. PubMed ID: 33903060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.